StreetAlpha
13F holdings · Q3 2026

Tri Locum Partners

New York, NY · files as Tri Locum Partners LP
Know the moment Tri Locum Partners filesYou follow Tri Locum Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1826434

Tri Locum Partners reported 18 stocks worth $506M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VRTX (13.7%), LLY (11.7%) and Teva Pharmaceutical Inds Ltd (9.6%). Compared with Q2 2026, the fund opened new positions in AMRX, CELC and VRDN, added to DNTH, trimmed VRTX, LLY and DXCM and sold out of TARS, ISRG and CYTK.

Latest filing: what Tri Locum Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
3 new2 added13 trimmed4 sold outBought about $88.7M · sold about $392M
New 3
Added 2
  • Teva Pharmaceutica+$18.9M+64%
  • DNTH+$5M+47%
Trimmed 13
See all 13 →
Sold out 4

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$506M−37.8% vs last quarter
Stocks held183 new · 4 sold out
Top 5 weight52.6%fairly concentrated
Turnover95%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
VRTX
Vertex Pharmaceuticals I
$69.5M13.7%133K−69K (−34%)3 of 8
2
LLY
Eli Lilly & Co
$59M11.7%51K−26K (−33%)4 of 8
3
TEVA PHARMACEUTICAL INDS LTD
$48.5M9.6%1.2M+477K (+64%)7 of 8
4
AMRX
Amneal Pharmaceuticals Inc
$46.9M9.3%2.3MNew position1 of 8
5
DXCM
Dexcom Inc
$42.2M8.3%489K−331K (−40%)4 of 8
6
JAZZ
Jazz Pharmaceuticals PLC
$37.1M7.3%160K−61K (−28%)4 of 8
7
ARGX
Argenx SE
$29.1M5.8%30K−11K (−27%)8 of 8
8
ASND
Ascendis Pharma A/s
$27M5.3%118K−140K (−54%)2 of 8
9
AXSM
Axsome Therapeutics Inc
$26.4M5.2%143K−76K (−35%)8 of 8
10
JNJ
Johnson & Johnson
$19.5M3.9%74K−351K (−83%)5 of 8
🔒 8 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
TARS
Tarsus Pharmaceuticals Inc
$20.7M328K
ISRG
Intuitive Surgical Inc
$19.1M48K
CYTK
Cytokinetics Inc
$16.5M194K
BBNX
Beta Bionics Inc
$7.7M493K

Reported value

last 8 quarters
$483MQ4 '24
$195MQ1 '25
$330MQ2 '25
$435MQ3 '25
$770MQ4 '25
$713MQ1 '26
$813MQ2 '26
$506MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Tri Locum Partners 13F FAQ

What does Tri Locum Partners own?

Tri Locum Partners reported 18 stocks worth $506M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VRTX (13.7%), LLY (11.7%) and Teva Pharmaceutical Inds Ltd (9.6%). The table above lists every position in the filing (the top 10 without an account).

What did Tri Locum Partners buy and sell in Q3 2026?

Compared with Q2 2026: 3 new positions, 2 added to, 13 trimmed and 4 sold out. New positions include AMRX, CELC and VRDN. It sold all of TARS, ISRG and CYTK.

When will Tri Locum Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Tri Locum Partners's portfolio worth?

The Q3 2026 filing reports $506M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.